Belluscura (LSE:BELL) Total Current Liabilities: £2.27 Mil (As of Jun. 2024)


What is Belluscura Total Current Liabilities?

Belluscura LSE:BELL Total Current Liabilities is £2.27 Mil as of Jun. 2024.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Belluscura's total current liabilities for the quarter that ended in Jun. 2024 was £2.27

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Belluscura Total Current Liabilities Related Terms

Belluscura Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Belluscura's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura Total Current Liabilities Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
Get a 7-Day Free Trial 0.29 0.17 0.82 2.50 2.43

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.39 2.50 1.48 2.43 2.27

Belluscura Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Belluscura's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.538+0.13
+Other Current Liabilities+Current Deferred Liabilities
=1.758+0
=2.43

Belluscura's Total Current Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.273+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=2.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of £2.27 Mil mean?
Belluscura (LSE:BELL) has a Total Current Liabilities of £2.27 Mil as of Jun. 2024. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Belluscura and its competitors.
Is Belluscura's Total Current Liabilities too high?
Belluscura's current Total Current Liabilities is £2.27 Mil.
How does Belluscura's Total Current Liabilities compare to ABT and BSX?
Belluscura's Total Current Liabilities of £2.27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Belluscura and its competitors. Belluscura's current Total Current Liabilities is £2.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current Total Current Liabilities of £2.27 Mil. The current Total Current Liabilities is £2.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current Total Current Liabilities is £2.27 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.